Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.810
+0.020 (1.12%)
Jun 25, 2025, 10:33 AM - Market open
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
120.14M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
MIST News
- 9 days ago - Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - GlobeNewsWire
- 2 months ago - Stock Picks From Seeking Alpha's March 2025 New Analysts - Seeking Alpha
- 3 months ago - Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil - Market Watch
- 3 months ago - US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Reuters
- 3 months ago - FDA Issues Complete Response Letter for Etripamil for PSVT - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha